featured
Selumetinib in Children With Recurrent Optic Pathway and Hypothalamic LGG Without NF1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neuro-Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study
Neuro-oncology 2021 Oct 01;23(10)1777-1788, J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, N Lindeman, O Campagne, A Banerjee, S Gururangan, LB Kilburn, S Goldman, I Qaddoumi, P Baxter, G Vezina, C Bregman, Z Patay, JY Jones, CF Stewart, MJ Fisher, LA Doyle, M Smith, IJ Dunkel, M FouladiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.